Shalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the sale, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. This trade represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

OS Therapies Price Performance

Shares of OSTX stock opened at $2.95 on Friday. OS Therapies Inc has a twelve month low of $1.58 and a twelve month high of $7.00. The stock has a fifty day moving average price of $3.32.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on OSTX shares. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of OS Therapies in a report on Wednesday. Maxim Group lifted their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.